Shares in Embattled Lynx Jump 11.6 Percent In Run-up to Next Week Q3 Report | GenomeWeb

NEW YORK, Nov. 11 (GenomeWeb News) - Shares in Lynx Therapeutics were up 11.6 percent at $2.99 in mid-afternoon Nasdaq trading, two days before the embattled company is to report its third-quarter earnings.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.